T
TRex Bio
Treg therapies for autoimmune and inflammatory diseases
About TRex Bio
TRexBio develops immunoregulatory medicines intended to restore immune balance in autoimmune and inflammatory diseases by acting on regulatory T cells in affected tissues. Its Deep Biology platform analyses gene expression, pathway activity and cell states in human tissue to identify where Treg function is disrupted and to inform target selection.
The lead wholly owned candidate, TRB-061, is a TNFR2 agonist designed to activate and expand Tregs in inflamed tissue, initially for moderate-to-severe atopic dermatitis. A second candidate, TRB-071, is a CD30 agonist designed to augment tissue Tregs and block inflammatory signalling. The company is based in South San Francisco and was founded in 2018, with scientific origins in tissue Treg biology at UCSF.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jan 2026 | $50M | $420M | Polaris Partners · Alexandria Venture Investments · Janus Henderson Investors · Balyasny Asset Management | ↗ |
| SERIES BOther financing | Nov 2024 | $84M | $336M | Polaris Partners · Johnson & Johnson Innovation · SV Health Investors · Alexandria Venture Investments | ↗ |
Growth signals
Latest recorded traffic for TRex Bio is 8.9K monthly website visits, up 147.2% over the last three months. TRex Bio's team grew 5.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
TRex Bio in the South San Francisco ecosystem
The TRex Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
SV Health Investors- PVPfizer Ventures
Johnson & Johnson Innovation
Alexandria Venture Investments
Eli Lilly
Polaris Partners
Laurion Capital Management
Delos Capital
Agent Capital- ACAvego Bioscience Capital
Series B and later3 investors entered at this stage
Janus Henderson Investors
Balyasny Asset Management
Affinity Asset Advisors
Other known investors1 additional known investor
University of Oxford
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TRex Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TRex Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








